Table 2. Treatment outcomes among eligible malaria patients in studies conducted under India’s National Antimalarial Drug Resistance Monitoring System, 2009–2010.
| Outcome after 28 days | No. (%) of patients infected |
|
|---|---|---|
| Plasmodium falciparum | Plasmodium vivax | |
| Primary classification | ||
| Adequate clinical and parasitological responsea | 1367 (94.0) | 185 (88.1) |
| Early treatment failureb | 3 (0.2) | 0 (0.0) |
| Late clinical failurec | 7 (0.5) | 0 (0.0) |
| Late parasitological failured | 17 (1.2) | 0 (0.0) |
| Lost to follow-up | 33 (2.3) | 12 (5.7) |
| Withdrawal after day 0 | 27 (1.8) | 13 (6.2) |
| PCR-corrected results | ||
| Recrudescence | 17 (63.0) | – |
| Reinfection | 2 (7.4) | – |
| Infection with other species | 7 (25.9) | – |
| Unknown | 1 (3.7) | – |
| Parasite clearance interval (h) | ||
| ≤ 24 | 873 (61.6) | 20 (10.5) |
| > 24 to 48 | 384 (27.1) | 88 (45.8) |
| > 48 to 72 | 154 (10.9) | 78 (40.6) |
| > 72 | 6 (0.4) | 6 (3.1) |
PCR, polymerase chain reaction.
a Absence of parasitaemia on day 28 without previous criteria for failure.
b Marked by the following, alone or in combination: danger signs for severe malaria on days 1, 2 or 3 in the presence of parasitaemia; parasitaemia level on day 2 higher than on day 0; parasitaemia level on day 3 more than 25% higher than on day 0; parasitaemia on day 3 plus fever.
c Danger signs for severe malaria and/or fever plus parasitaemia from day 4 to day 28.
d Parasitaemia from day 7 to day 28 even if patient afebrile.